347174-05-4 Usage
Description
Ferrostatin-1 (Fer-1) is a potent and selective inhibitor of ferroptosis, an iron-dependent form of nonapoptotic cell death. It has been shown to inhibit ferroptosis in cancer cells and glutamate-induced cell death in organotypic rat brain slices. Additionally, Fer-1 blocks the cytotoxic effects of sorafenib in hepatocellular carcinoma cells and inhibits oxidative lipid damage and cell death in various disease models. It also prevents apoptosis of renal proximal tubular cells induced by reactive oxygen species.
Uses
Used in Pharmaceutical Industry:
Ferrostatin-1 (Fer-1) is used as a potent inhibitor of ferroptosis for the development of therapeutic agents targeting cancer cells and other diseases involving oxidative stress and cell death.
Used in Neuroscience Research:
Ferrostatin-1 (Fer-1) is used as a research tool for studying the mechanisms of glutamate-induced cell death in organotypic rat brain slices, which can help in understanding and developing treatments for neurodegenerative diseases.
Used in Hepatocellular Carcinoma Treatment:
Ferrostatin-1 (Fer-1) is used as a protective agent against the cytotoxic effects of sorafenib in hepatocellular carcinoma cells, potentially improving treatment outcomes for liver cancer patients.
Used in Oxidative Stress and Cell Death Research:
Ferrostatin-1 (Fer-1) is used as an inhibitor of oxidative lipid damage and cell death in various disease models, aiding in the study of the underlying mechanisms of these processes and the development of novel therapeutic strategies.
Used in Renal Proximal Tubular Cell Protection:
Ferrostatin-1 (Fer-1) is used as a protective agent to prevent apoptosis of renal proximal tubular cells induced by reactive oxygen species, which can contribute to the development of treatments for kidney diseases and injury.
Biochem/physiol Actions
Ferrostatin-1 is an active radical-trapping antioxidant that traps peroxyl radicals, and thus serves as a potential inhibitor of ferroptosis. Ferroptosis is considered as regulated necrosis, which differs from apoptosis and autophagy. Ferrostatin-1 is known to show protective effects against Huntington′s disease and also prevents neurotoxicity induced by glutamate in cellular models.
References
1) Dixon et al. (2012), Ferroptosis: an iron-dependent form of nonapoptotic cell death; Cell, 149 1060
2) Louandre et al. (2013), Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib; Int. J. Cancer, 133 1732
3) Skouta et al. (2014), Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models; J. Am. Chem. Soc., 136 4551
4) Nowak et al. (2013), Protein kinase C-α interaction with iHSP70 in mitochondria promotes recovery of mitochondrial function after injury in renal proximal tubular cells; Am. J. Physiol. Renal. Physiol., 305 F764
Check Digit Verification of cas no
The CAS Registry Mumber 347174-05-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,4,7,1,7 and 4 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 347174-05:
(8*3)+(7*4)+(6*7)+(5*1)+(4*7)+(3*4)+(2*0)+(1*5)=144
144 % 10 = 4
So 347174-05-4 is a valid CAS Registry Number.
347174-05-4Relevant articles and documents
COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS
-
Paragraph 0174, (2020/06/19)
The present disclosure provides, inter alia, a compound having the structure (1). Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods f
Novel arylalkylamine compounds exhibits potent selective antiparasitic activity against Leishmania major
Iniguez, Eva A.,Perez, Andrea,Maldonado, Rosa A.,Skouta, Rachid
supporting information, p. 5315 - 5320 (2015/11/09)
Leishmania major (L. major) is a protozoan parasite causal agent of Leishmaniasis. It is estimated that 12 million people are currently infected and around 2 million infections occur each year. Current treatments suffer of high toxicity for the patient, low efficacy toward the parasite, high cost, and are losing effectiveness due to parasite resistance. Discovering novel small molecule with high specificity/selectivity and drug-like properties for anti-leishmanial activity remains a significant challenge. The purpose of this study is to communicate the design and synthesis strategies of novel chemical compounds based of the arylalkylamine scaffold with selective toxicity towards L. major and less toxicity to human cells in vitro. Here, we have developed a structure activity relationship (SAR) study of arylalkylamine AA1 in order to study their anti-parasitic effect in L. major. Overall, 27 arylalkylamine compounds derived from AA1 were synthesized and purified by silica gel column chromatography. The purity of each analog was confirmed by spectroscopic methods (1H, 13C NMR and LC/MS). Among these analogs, the compound AA9 showed the best toxic activity on L. major (LD50 = 3.34 μM), which represents a 9 fold higher lethality as compared with its parental AA1 (Fer-1) compound (LD50 = 28.75 μM). In addition, AA9 showed no significant toxicity at 80 μM on U20S Human Osteoblasts, Raw 264.7 Macrophages or intraperitoneal macrophages. In summary, our combined SAR study and biological evaluation data of AA1-AA27 compounds allow the identification of novel arylalkylamine compound AA9 that exhibits potent cytotoxicity against L. major promastigote with minimum toxic effect on human cells.
COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS
-
Paragraph 0174; 0181; 0187, (2013/10/22)
The present invention provides, inter alia, a compound having the structure: (Formula (I). Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.
